Research ExplorerPublicationsUnrelated cord blood transplantation for patients with prima...

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis

Standard

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. / Robin, Marie; Giannotti, Federica; Deconinck, Eric; Mohty, Mohamad; Michallet, Mauricette; Sanz, Guillermo; Chevallier, Patrice; Cahn, Jean-Yves; Legrand, Faezeh; Rovira, Montserrat; Passweg, Jakob; Sierra, Jorge; Nguyen, Stephanie; Maillard, Natacha; Yakoub-Agha, Ibrahim; Linkesch, Werner; Cannell, Paul; Marcatti, Magda; Bay, Jacques-Olivier; Chalandon, Yves; Kröger, Nicolaus; Gluckman, Eliane; Rocha, Vanderson; Olavarria, Eduardo; Ruggeri, Annalisa; Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT).

In: BIOL BLOOD MARROW TR, Vol. 20, No. 11, 01.11.2014, p. 1841-6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Robin, M, Giannotti, F, Deconinck, E, Mohty, M, Michallet, M, Sanz, G, Chevallier, P, Cahn, J-Y, Legrand, F, Rovira, M, Passweg, J, Sierra, J, Nguyen, S, Maillard, N, Yakoub-Agha, I, Linkesch, W, Cannell, P, Marcatti, M, Bay, J-O, Chalandon, Y, Kröger, N, Gluckman, E, Rocha, V, Olavarria, E, Ruggeri, A & Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT) 2014, 'Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis', BIOL BLOOD MARROW TR, vol. 20, no. 11, pp. 1841-6. https://doi.org/10.1016/j.bbmt.2014.06.011

APA

Robin, M., Giannotti, F., Deconinck, E., Mohty, M., Michallet, M., Sanz, G., Chevallier, P., Cahn, J-Y., Legrand, F., Rovira, M., Passweg, J., Sierra, J., Nguyen, S., Maillard, N., Yakoub-Agha, I., Linkesch, W., Cannell, P., Marcatti, M., Bay, J-O., ... Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT) (2014). Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. BIOL BLOOD MARROW TR, 20(11), 1841-6. https://doi.org/10.1016/j.bbmt.2014.06.011

Vancouver

Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G et al. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. BIOL BLOOD MARROW TR. 2014 Nov 1;20(11):1841-6. https://doi.org/10.1016/j.bbmt.2014.06.011

Bibtex

@article{90fddc229f9141a68fb71f11ec34a97e,
title = "Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis",
abstract = "To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.",
author = "Marie Robin and Federica Giannotti and Eric Deconinck and Mohamad Mohty and Mauricette Michallet and Guillermo Sanz and Patrice Chevallier and Jean-Yves Cahn and Faezeh Legrand and Montserrat Rovira and Jakob Passweg and Jorge Sierra and Stephanie Nguyen and Natacha Maillard and Ibrahim Yakoub-Agha and Werner Linkesch and Paul Cannell and Magda Marcatti and Jacques-Olivier Bay and Yves Chalandon and Nicolaus Kr{\"o}ger and Eliane Gluckman and Vanderson Rocha and Eduardo Olavarria and Annalisa Ruggeri and {Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT)}",
note = "Copyright {\textcopyright} 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = nov,
day = "1",
doi = "10.1016/j.bbmt.2014.06.011",
language = "English",
volume = "20",
pages = "1841--6",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis

AU - Robin, Marie

AU - Giannotti, Federica

AU - Deconinck, Eric

AU - Mohty, Mohamad

AU - Michallet, Mauricette

AU - Sanz, Guillermo

AU - Chevallier, Patrice

AU - Cahn, Jean-Yves

AU - Legrand, Faezeh

AU - Rovira, Montserrat

AU - Passweg, Jakob

AU - Sierra, Jorge

AU - Nguyen, Stephanie

AU - Maillard, Natacha

AU - Yakoub-Agha, Ibrahim

AU - Linkesch, Werner

AU - Cannell, Paul

AU - Marcatti, Magda

AU - Bay, Jacques-Olivier

AU - Chalandon, Yves

AU - Kröger, Nicolaus

AU - Gluckman, Eliane

AU - Rocha, Vanderson

AU - Olavarria, Eduardo

AU - Ruggeri, Annalisa

AU - Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT)

N1 - Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.

AB - To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.

U2 - 10.1016/j.bbmt.2014.06.011

DO - 10.1016/j.bbmt.2014.06.011

M3 - SCORING: Journal article

C2 - 24946719

VL - 20

SP - 1841

EP - 1846

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 11

ER -